Calithera Biosciences
Market Cap
US$213.5m
Last Updated
2019/08/21 00:55 UTC
Data Sources
Company Financials +
Executive Summary
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States.
Snowflake
Fundamentals
Flawless balance sheet and fair value.
Risks
- Calithera Biosciences has significant price volatility in the past 3 months.
Share Price & News
How has Calithera Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
2.6%
NasdaqGS:CALA
0.2%
US Biotechs
0.2%
US Market
1 Year Return
-16.4%
NasdaqGS:CALA
-9.1%
US Biotechs
-0.7%
US Market
CALA underperformed the Biotechs industry which returned -7.3% over the past year.
CALA underperformed the Market in United States of America which returned 0.3% over the past year.
Share holder returns
| CALA | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.6% | 0.2% | 0.2% |
| 30 Day | -4.1% | 0.9% | -2.7% |
| 90 Day | -30.6% | 2.4% | 1.6% |
| 1 Year | -16.4%-16.4% | -8.4%-9.1% | 1.6%-0.7% |
| 3 Year | 26.4%26.4% | 8.3%4.6% | 40.0%30.9% |
| 5 Year | n/a | 4.5%-0.3% | 53.8%36.8% |
Price Volatility Vs. Market
How volatile is Calithera Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Do Institutions Own Shares In Calithera Biosciences, Inc. (NASDAQ:CALA)?3 weeks ago | Simply Wall St
If You Had Bought Calithera Biosciences (NASDAQ:CALA) Stock Three Years Ago, You Could Pocket A 37% Gain Today1 month ago | Simply Wall St
Did Calithera Biosciences, Inc. (NASDAQ:CALA) Insiders Buy Up More Shares?Valuation
Is Calithera Biosciences undervalued based on future cash flows and its price relative to the stock market?
48%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Calithera Biosciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
Calithera Biosciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Calithera Biosciences is loss making, we can't compare its value to the US Biotechs industry average.
Calithera Biosciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Calithera Biosciences, we can't assess if its growth is good value.
Price Based on Value of Assets
Calithera Biosciences is good value based on assets compared to the US Biotechs industry average.
Next Steps
Future Growth
How is Calithera Biosciences expected to perform in the next 1 to 3 years based on estimates from 3 analysts?
5.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Calithera Biosciences's revenue is expected to grow significantly at over 20% yearly.
Calithera Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
Calithera Biosciences's revenue growth is expected to exceed the United States of America market average.
Unable to compare Calithera Biosciences's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
Unable to compare Calithera Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Calithera Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Calithera Biosciences performed over the past 5 years?
-21.7%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Calithera Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Calithera Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Calithera Biosciences's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Calithera Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Calithera Biosciences has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Calithera Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Calithera Biosciences's financial position?
Financial Position Analysis
Calithera Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Calithera Biosciences's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Calithera Biosciences has no debt.
Calithera Biosciences has not taken on any debt in the past 5 years.
Balance Sheet
Low level of unsold assets.
Calithera Biosciences has no debt, it does not need to be covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Calithera Biosciences has sufficient cash runway for 2.1 years based on current free cash flow.
Calithera Biosciences has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 54.6% each year.
Next Steps
Dividend
What is Calithera Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Calithera Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Calithera Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Calithera Biosciences has not reported any payouts.
Unable to verify if Calithera Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Calithera Biosciences has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Calithera Biosciences's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Calithera Biosciences's salary, the management and board of directors tenure and is there insider trading?
3.0yrs
Average management tenure
CEO
Susan Molineaux (65yo)
9.4yrs
Tenure
US$2,033,057
Compensation
Dr. Susan M. Molineaux, Ph.D., Co-founded Calithera Biosciences, Inc. in June 2010 and has been its Chief Executive Officer and President since June 2010. Dr. Molineaux also serves as Principal Financial O ...
CEO Compensation Analysis
Susan's remuneration is higher than average for companies of similar size in United States of America.
Susan's compensation has increased whilst company is loss making.
Management Age and Tenure
3.0yrs
Average Tenure
48yo
Average Age
The tenure for the Calithera Biosciences management team is about average.
Board Age and Tenure
4.3yrs
Average Tenure
55.5yo
Average Age
The tenure for the Calithera Biosciences board of directors is about average.
Insider Trading
More shares have been bought than sold by Calithera Biosciences individual insiders in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer Co-Founder |
| Shares | 51,600 |
| Max Price | US$3.88 |
Ownership Breakdown
Management Team
Susan Molineaux (65yo)
Co-Founder
- Tenure: 9.4yrs
- Compensation: US$2.03m
Christopher Molineaux (66yo)
Senior Vice President of Development
- Tenure: 6.3yrs
- Compensation: US$446.60k
Eric Sjogren (62yo)
Senior Vice President of Drug Discovery
- Tenure: 9.2yrs
- Compensation: US$959.51k
Stephanie Wong (45yo)
Senior VP of Finance & Secretary
- Tenure: 0.0yrs
Sumita Ray (45yo)
Senior VP
- Tenure: 1.8yrs
- Compensation: US$1.26m
Hagit Glickman
Head of People & Culture
- Tenure: 0.0yrs
Curtis Hecht (48yo)
Chief Business Officer
- Tenure: 0.6yrs
- Compensation: US$883.44k
Keith Orford (47yo)
Chief Medical Officer
- Tenure: 3.3yrs
- Compensation: US$1.14m
Jennifer McNealey
Vice President of Investor Relations & Strategy
- Tenure: 2.7yrs
Sam Whiting
Senior Vice President of Clinical Development
- Tenure: 0.6yrs
Board Members
Jean George (61yo)
Director
- Tenure: 6.9yrs
- Compensation: US$98.30k
Henry Wolff (70yo)
Director
- Tenure: 4.7yrs
- Compensation: US$97.30k
Deepa Pakianathan (54yo)
Lead Independent Director
- Tenure: 2.6yrs
- Compensation: US$120.30k
Susan Molineaux (65yo)
Co-Founder
- Tenure: 9.4yrs
- Compensation: US$2.03m
John Drachman (57yo)
Director
- Tenure: 5.7yrs
- Compensation: US$87.30k
Sunil Agarwal (49yo)
Independent Director
- Tenure: 3.9yrs
- Compensation: US$93.80k
Suzy Jones (53yo)
Director
- Tenure: 3.0yrs
- Compensation: US$89.80k
Blake Wise (48yo)
Director
- Tenure: 1.9yrs
- Compensation: US$86.05k
Company Information
Calithera Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Calithera Biosciences, Inc.
- Ticker: CALA
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$213.486m
- Shares outstanding: 53.77m
- Website: https://www.calithera.com
Number of Employees
Location
- Calithera Biosciences, Inc.
- 343 Oyster Point Boulevard
- Suite 200
- South San Francisco
- California
- 94080
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CALA | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Oct 2014 |
| 2CB | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 2014 |
Biography
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/08/21 00:55 |
| End of Day Share Price | 2019/08/20 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.